Acta Med. 1997, 40: 99-102
https://doi.org/10.14712/18059694.2020.53
Fenfluramine Challenge Test in Obsessive-Compulsive Disorder - First Results
References
1. DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive- compulsive disorder. Arch Gen Psychiatry 1988; 45:177-85.
2. E, Lopez-Ibor AJ. La monoclomipramina en enfermost psiquiatricos resistentes a otros tratamientos. Acta Luso-Esp Neurol Psiq Ciene Afines 1967; 26:119-47.
3. WK, Price LH, Delgado PL et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive- compulsive disorder. Arch Gen Psychiatry 1990; 47:577-85.
4. WK, Price LH, Rasmussen SA et al. Yale-Brown Obsessive-Compulsive Scale. Arch Gen Psychiatry 1989; 46:1006-16.
5. Goodman WK, Price LH, Woods SW, Charney DS. Pharmacologic challenges in obsessive compulsive disorder. In: Zohar J, Insel T, Rasmussen S, (Eds.). The Psychobiology of Obsessive-compulsive disorder. New York: Springer Verlag 1991;162-86.
6. WK, McDougle C, Price LH et al. m-Chlorophenylpiperazine in patiens with obsessive compulsive disorder: absence of symptom exacerbation. Biol Psychiatry 1995; 38:138-49.
7. M. A rating scale for depression. Neurol Neurosurg Psychiat 1960; 23:562.
8. Hewlett WA, Martin K. Fenfluramine challenges and serotonergic functioning in obsessive compulsive disorder. Presented at First International Obsessive-compulsive disorder Congress, Capri, Italy, 1993, 12-13 Mar.
9. E, DeCaria CM, Nitescu A et al. Serotonergic function in obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:21-8.
10. E, Fay M, Cohen B, Campeas R, Gorman JM, Liebovitz MR. Serotonergic and adrenergic sensitivity in obsessive-compulsive disorder: Behavioral findings. Am J Psychiatry 1988; 145:1015-17.
11. TR, Donnelly EF, Lalakea ML et al. Neurological and neuropsychological studies of patients with obsessivecompulsive disorder. Biol Psychiatry 1983; 18:741-51.
12. JV, O Keane V, Butcher G, Dinan GT. Cortisol and prolactin responses to d-fenfluramine in normotensive obsessive disorder, a comparison with depressed and healthy controls. Br J Psychiatry 1992; 161:517-21.
13. JV, Butcher G, Clare AW, Dinan TG. Buspironeinduced prolactin responses in obsessive compulsive disorder. Int J Psychopharmacology 1992; 7:45-9.
14. JV, Butcher G, Clare AW, Dinan TG. The anterior pituitary responds to prolactin in obsessive compulsive disorder : evidence to support a neuroendocrine serotonergic deficit. Acta Psychiatr Scand 1993; 87:384-8.
15. PA, DeMeo MD, Sweeney JA, Halper J, Mann JJ, Shear MK. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist d-fenfluramine in adults with obsessive compulsive disorder. Biol Psychiatry 1992; 164:19-34.
16. SA. Clomipramine in obsessional neurosis: a placebo-controlled trial. Pharm Med 1980; 1:189-92.
17. SA, McIntyre A, Sterheider M et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive compulsive disorder. Eur Neuropsychopharmacology 1993; 3:143-52.
18. TA, Yoney TH, L Heureux F. Serotonergic responsivity to m-CPP in OCD patients during clomipramine and fluoxetine treatment. Biol Psychiatry 1990; 27:14A-17A.
19. LH, Charney DS, Delgado PL, Anderson GM, Heninger GR. Effects of desipramine and fluvoxamine treatment on the prolactin response: Serotonin function and the mechanism of antidepressant action. Arch Gen Psychiatry 1989; 46:625-31.
20. RP, Joffe RT. Biological challenges in obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12:269-75.
21. GD, Rampey AH, Potvin JH et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive compulsive disorder. Arch Gen Psychiatry 1994; 51:559-67.
22. J, Mueller EA, Insel TR. Serotonin responsivity in obsessive compulsive disorder. Arch Gen Psychiatry 1987; 44:946-51.
